로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Licensing > BNO202203

DHODH inhibitor

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: DHODH inhibitor
    Indications: IBD, expanded indication COVID-19
    Research phase: IND ready
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA: High selectivity of inhibiting DHODH, Blocking the DHODH synthesis pathway can effectively inhibit the proliferation of activated immune cells and the secretion of cytokines.



    2. Significant preclinical efficacy and less toxic & side effects.


    1) Improve weight loss and disease activity score DIA in mice


    2) Significant improvement in inflammation-induced increase in colon density and colonic weight gain


    3) Anti-coronavirus activity


    3. Global competitiveness:


    BIC Potential. So far, there is no effective drug to cure IBD on the market, and the preclinical data of the target project is better than the fastest developing IMU-838.



    4. Good market potential:



    It is estimated that in 2025, the global IBD market will reach 11 billion US dollars. China will have more than 1.5 million IBD patients, and the drug market will be 16.6 billion yuan, with a compound annual growth rate of 14.26%.


  • Project Introduction

    1. Asset type: DHODH inhibitor

    2. Indication: IBD, expanded indication COVID-19

    3. Research phase: IND ready

    4. Cooperation demands:   License-out or co-development

    5. Research progress:

    1.Completed preclinical development and ready for IND filing.

    2.In vitro study, all indicators of this DHODH inhibitor are equal to or better than IMU-838.

    3.The selective inhibitor improved body weight loss and disease activity score DIA, and significantly improved inflammation-induced colon density and colon weight gain in a mouse model of IBD.

    4.The safety test has been completed, and there are no obvious toxic and side effects.

Comments (0)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

New Product Launch

Questions & Comments